Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM

Diabetes Care. 1997 Mar;20(3):381-4. doi: 10.2337/diacare.20.3.381.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose / analysis*
  • Blood Glucose / metabolism
  • C-Peptide / blood
  • C-Peptide / metabolism
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Glucagon / blood
  • Glucagon / metabolism
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptides
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Injections, Subcutaneous
  • Insulin / administration & dosage
  • Insulin / blood
  • Insulin / therapeutic use*
  • Male
  • Middle Aged
  • Pancreatic Polypeptide / blood
  • Pancreatic Polypeptide / metabolism
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / therapeutic use*
  • Time Factors

Substances

  • Blood Glucose
  • C-Peptide
  • Hypoglycemic Agents
  • Insulin
  • Peptide Fragments
  • glucagon-like peptide 1 (7-36)amide
  • Pancreatic Polypeptide
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide 1
  • Glucagon